Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · IEX Real-Time Price · USD
145.69
+1.55 (1.08%)
At close: Jul 19, 2024, 4:00 PM
158.45
+12.76 (8.76%)
Pre-market: Jul 22, 2024, 4:08 AM EDT
Neurocrine Biosciences Stock Forecast
Stock Price Forecast
The 22 analysts with 12-month price forecasts for NBIX stock have an average target of 156.45, with a low estimate of 100 and a high estimate of 216. The average target predicts an increase of 7.39% from the current stock price of 145.69.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for NBIX stock from 23 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 9 | 8 | 9 | 10 | 10 | 10 |
| Hold | 6 | 6 | 6 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 22 | 21 | 22 | 23 | 23 | 23 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $160 → $170 | Buy | Maintains | $160 → $170 | +16.69% | Jul 12, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $169 → $173 | Buy | Maintains | $169 → $173 | +18.75% | Jul 10, 2024 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $160 | Buy | Maintains | $160 | +9.82% | Jun 12, 2024 |
| Wedbush | Wedbush | Buy Reiterates $152 | Buy | Reiterates | $152 | +4.33% | May 29, 2024 |
| UBS | UBS | Strong Buy Maintains $174 → $193 | Strong Buy | Maintains | $174 → $193 | +32.47% | May 28, 2024 |
Financial Forecast
Revenue This Year
2.27B
from 1.89B
Increased by 20.03%
Revenue Next Year
2.61B
from 2.27B
Increased by 15.23%
EPS This Year
4.15
from 2.47
Increased by 67.94%
EPS Next Year
6.48
from 4.15
Increased by 56.32%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.5B | 3.0B | 3.7B | 4.4B | 5.1B |
| Avg | 2.3B | 2.6B | 3.0B | 3.4B | 3.9B |
| Low | 2.1B | 2.3B | 2.4B | 3.0B | 3.3B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 31.7% | 31.7% | 40.4% | 43.8% | 46.9% |
| Avg | 20.0% | 15.2% | 16.4% | 13.5% | 13.6% |
| Low | 12.9% | 0.3% | -8.5% | -2.7% | -5.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 5.79 | 8.95 | 11.48 | 16.13 | 18.54 |
| Avg | 4.15 | 6.48 | 8.88 | 13.11 | 15.36 |
| Low | 2.70 | 4.68 | 6.20 | 10.20 | 12.83 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 134.2% | 115.7% | 77.0% | 81.6% | 41.4% |
| Avg | 67.9% | 56.3% | 37.0% | 47.7% | 17.1% |
| Low | 9.5% | 12.9% | -4.3% | 14.9% | -2.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.